A Phase 4 interventional study of piroxicam and valdecoxib in Dysmenorrhea, sponsored by Pfizer. Completed at 10 sites in Brazil. Open to female participants aged 18 Years to 44 Years. Per ClinicalTrials.gov, last updated 2018-12-05.
Sponsored by Pfizer · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Dysmenorrhea with a site in Brazil — 2 open to participants now, 2 under way, 1 of them phase 3. Dysmenorrhea · Brazil.
Among the 10 studies in Dysmenorrhea with a site in Brazil, this one is the only one that started in 2003, is one of 2 in phase 4, and was the 1st registered.
432 studies on the registry are indexed under Dysmenorrhea; 109 are open to participants now.
Browse Dysmenorrhea studies →2 of the 10 studies in Dysmenorrhea with a site in Brazil are open now. Recruiting first, the newest first:
Hospital de Clinicas de Porto Alegre · Sites in Brazil
Ages 18–45 · Women only
EMS · Sites in Brazil
Ages 16–35 · Women only
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 59 Dysmenorrhea studies recruiting now, 7 (12%) set no upper age limit and 51 (86%) stop at 75 or younger; 11 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 44 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 154 is above the median of 62 across 364 interventional studies indexed under Dysmenorrhea.
Median enrollment 100 across the 9 interventional studies. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 10 have an industry lead sponsor. The 9 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 2 studies filed under Dysmenorrhea — fewer than ten, so there is no comparison to draw.
1 of the studies in Dysmenorrhea with a site in Brazil that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07733583Hospital de Clinicas de Porto AlegrePelvic Floor Physical Therapy and Exercise for Women With Endometriosis and Chronic Pelvic Pain | 2027-09-14 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Dysmenorrhea with a site in Brazil, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To compare the analgesic efficacy, safety, and tolerability of valdecoxib versus piroxicam in subjects with moderate to severe menstrual cramping pain associated with primary dysmenorrhea.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: piroxicam
Drug: valdecoxib
piroxicam 40 mg capsule QD for up to the first 3 days of the menstrual cycle
valdecoxib 40 mg capsule twice a day (BID), taken as required, on the first day of treatment in the menstrual cycle followed by oral valdecoxib 40 mg once a day (QD) for up to the first 3 days of the menstural cycle
Total pain relief were calculated as the summed weighted pain releif scores
Time frame: 8 hours
adverse events
Time frame: approximately 5 days after treated cycle
laboratory analyses
Time frame: screening
Subjects' global evaluation of the study drug
Time frame: 8 hours and 72 hours
Summed pain intensity difference
Time frame: 8 hours
Percent of subjects who took rescue medication
Time frame: 72 hours
Percent of subjects who took the second dose of study medication
Time frame: 72 hours
The record gives a start of Jan 2003 and a completion of Jul 2003. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Piroxicam · Valdecoxib